Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 16;9(1):183.
doi: 10.1038/s41420-023-01446-6.

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target

Affiliations

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target

Arwin Groenewoud et al. Cell Death Discov. .

Abstract

Uveal melanoma (UM) has a high risk to progress to metastatic disease with a median survival of 3.9 months after metastases detection, as metastatic UM responds poorly to conventional and targeted chemotherapy and is largely refractory to immunotherapy. Here, we present a patient-derived zebrafish UM xenograft model mimicking metastatic UM. Cells isolated from Xmm66 spheroids derived from metastatic UM patient material were injected into 2 days-old zebrafish larvae resulting in micro-metastases in the liver and caudal hematopoietic tissue. Metastasis formation could be reduced by navitoclax and more efficiently by the combinations navitoclax/everolimus and flavopiridol/quisinostat. We obtained spheroid cultures from 14 metastatic and 10 primary UM tissues, which were used for xenografts with a success rate of 100%. Importantly, the ferroptosis-related genes GPX4 and SLC7A11 are negatively correlated with the survival of UM patients (TCGA: n = 80; Leiden University Medical Centre cohort: n = 64), ferroptosis susceptibility is correlated with loss of BAP1, one of the key prognosticators for metastatic UM, and ferroptosis induction greatly reduced metastasis formation in the UM xenograft model. Collectively, we have established a patient-derived animal model for metastatic UM and identified ferroptosis induction as a possible therapeutic strategy for the treatment of UM patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Generation of highly metastatic uveal melanoma in zebrafish from spheroid cultures.
A Scheme representing the approach to inject metastatic uveal melanoma in zebrafish. Spheroid cultures are reduced to single cell suspensions by enzymatic dissociation, and single cells are injected through the Duct of Cuvier (doC) into the blood circulation of 48 hpf Tg(fli:GFPx casper) zebrafish larvae, in which all vessels are labelled with GFP (green). B Stereomicroscopic images of representative phenotypes of Tg(fliGFPx casper) zebrafish larvae 6 days post injection with lentivirally labelled cells (red) derived from the commonly used UM cell lines Omm2.3 and Xmm66 compared to spheroid-derived Xmm66 cells (spXmm66). Scale bars: 100 μm. Inserts: same fish imaged with bright field microscopy. C Quantitative analysis of the metastatic capacity of adherent uveal melanoma Omm2.3 and Xmm66 cells and UM-derived spheroid line spXmm66 upon engraftment into zebrafish (n = 20). Data are mean ± SD. D Analysis of spXmm66 by H&E as well as melanA staining (marker for the melanocytic origin of the engrafted cells). E Microscopic images of the spXmm66 spheroid line in suspension after lentiviral transduction resulting in tdTomato expression. F Representative images of tissue sections of zebrafish engrafted with spXmm66 cells 6 days post injection stained for hematoxylin and eosin and BAP1 (dark purple, boxed area) or melanA (dark purple, boxed area). Scale bars: 1 mm (overview image), 500 µm (magnification). G Stereomicroscopic images of representative phenotypes of Tg(fliGFPx casper) zebrafish larvae 6 days post injection with tdTomato-labelled spXmm66 cells grown in suspension (spheroid) or as de novo adherent cultures (7 days conventional cell culture on plastic). Scale bars: 100 μm. Inserts: same fish imaged with bright field microscopy. H Quantitative analysis of the metastatic capacity of spXmm66 cells grown in suspension (spheroid) or as de novo adherent cultures upon engraftment into zebrafish (n = 20). Data are mean ± SD. ns: not significant. **:p < 0.01; ***:p < 0.001.
Fig. 2
Fig. 2. Spheroid cultures can readily be established from both primary uveal melanoma tumors and patient-derived metastatic uveal melanoma tissues derived from murine xenografts.
A Representative image of the established spheroid cultures. Primary: uveal melanoma patient tumor tissue. Metastatic: murine xenograft material, derived from metastatic UM samples propagated subcutaneously. Scale bars: 250 µm). B Analysis of spXmm26 by H&E as well as melanA staining (marker for the melanocytic origin of the engrafted cells). C Stereomicroscopic images of representative phenotypes of Tg(fliGFPx casper) zebrafish larvae (blood vessels: green) 6 days post injection with CM-DiL-labelled spheroid cells (spUM-LB048 and spUM-LB049, red) derived from primary uveal melanoma tumor tissues. Note, disseminated cancer cells are present up to 6 days post engraftment and settle in both the hematopoietic tissue and/or the liver. Inserts: same fish imaged with bright field microscopy.
Fig. 3
Fig. 3. Metastatic uveal melanoma zebrafish model is suitable for drug screening.
A Scheme representing the approach to perform drug screening in the here established metastatic uveal melanoma zebrafish model utilizing spXmm66 cell engraftment at 48 hpf followed by tumor burden analysis 6 dpi. BD Stereomicroscopic images of representative phenotypes of Tg(fliGFPx casper) zebrafish larvae 6 days post injection with tdTomato-labelled spXmm66 cells and treatment with the indicated drugs at their maximum tolerated dose (>80% survival, Supplementary Fig. 1). Scale bars: 250 µm. E Quantitative analysis of (BD) to determine the effect of the indicated drug treatment on tumor burden, normalized to DMSO control (normalized tumor burden). Data are mean ± SD. *:p < 0.05; **:p < 0.01; ***:p < 0.001.
Fig. 4
Fig. 4. Ferroptosis-related genes negatively correlate with uveal melanoma patient survival.
A, Analysis of the UM-specific survival in both LUMC and TCGA patient cohorts. B, C High GPX4 (B) and SLC7A11 (C) expression levels (divided over the median) show a correlation with reduced patient survival (p = 0.004 and p = 0.0014, respectively). D, E Comparative analysis of the relation between GPX4 (D) and SLC7A11 (E) and survival in BAP1+ (LUMC, determined by IHC, n = 25) and BAP1 high (TCGA, determined by RNAseq, n = 40) UM samples compared to survival in BAP1- (LUMC, IHC, n = 31) and BAP1 low (TCGA, RNAseq, n = 40) UM samples. The expression levels of GPX4, SLC7A11 and BAP1 were split at the median, and curves were plotted using SPSS.
Fig. 5
Fig. 5. Ferroptosis induction inhibits metastasis formation in the metastatic uveal melanoma zebrafish model.
A Western blot analysis determining GPX4, SLC7A11 and BAP1 protein expression in the two established cell lines MM66 and MM 46 and eight patient-derived tissues. Loading control: vinculin. Note, while BAP1 and GPX4 show a negative correlation in the patient samples, SLC7A11 was barely detected, independent of BAP1 expression levels. B, B’ Westernblot quantification of BAP1, SLC7A11 and GPX4. C qPCR analysis of GPX4 mRNA expression in primary UM tissues and spXmm66 (green dots), with known BAP1 status. Expression values were normalized to GAPDH (ΔCT). n = 3. D Quantitative analysis of tumor burden in the here established metastatic uveal melanoma zebrafish model. The indicated cells were engrafted at 48 hpf, maintained for 6 days in the absence or presence of the ferroptosis inducer erastin (SLC7A11 inhibitor, 5 μM) or RSL3 (GPX4 inhibitor, 10 μM) and subsequently subjected to tumor burden analysis. Notably, ferroptosis induction via erastin and/or RSL3 resulted in 4 out of 5 cases in a significant reduction of tumor burden. n = 40 (spXmm66) or n = 20 (all other cases). Data are mean ± SD. D3: chromosome 3 disomy: M3: chromosome 3 monosomy. ns: not significant. ***:p < 0.001.

References

    1. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44. doi: 10.1136/bjophthalmol-2016-309034. - DOI - PMC - PubMed
    1. Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6:24. doi: 10.1038/s41572-020-0158-0. - DOI - PubMed
    1. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3. doi: 10.1126/science.1194472. - DOI - PMC - PubMed
    1. Lane AM, Kim IK, Gragoudas ES. Survival rates in patients after treatment for metastasis from uveal melanoma. JAMA Ophthalmol. 2018;136:981–6. doi: 10.1001/jamaophthalmol.2018.2466. - DOI - PMC - PubMed
    1. Rossi E, Pagliara MM, Orteschi D, Dosa T, Sammarco MG, Caputo CG, et al. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Cancer Immunol Immunother. 2019;68:1179–85. doi: 10.1007/s00262-019-02352-6. - DOI - PMC - PubMed

LinkOut - more resources